The association between mutations in the Hepatitis B Surface antigen (HBsAg) gene and the occurrence of occult HBV (OBI) in patients has not been studied adequately to determine if the two are correlated. The current study was aimed to investigate HBsAg mutations, the genotype of HBV and co-infection with HCV in OBI in the central part of Iran to determine any possible associations.
Introduction
Iran is classified as having low endemicity for hepatitis B infection [1] .
Despite all blood and blood components being screened in Iran for the Hepatitis B surface antigen (HBsAg, also referred to as the S-gene), some cases of post-transfusion hepatitis B have been reported [2] . Occult HBV infection (OBI) is a clinical form of hepatitis B in which, despite undetectable serum levels of HBsAg, HBV-DNA is present in the serum of patients [3] [4] [5] . This type of hepatitis creates severe problems for blood transfusion services worldwide as it creates an avenue for posttransfusion infection despite the efforts of these services to screen for potential carriers of the disease. Studies showed that one of the main causes of post-transfusion hepatitis B infection could be OBI [6] , however, the mechanism(s) responsible for progression of OBI has yet to be clarified. Recently we reported OBI in Isfahan and Kerman, two of the central provinces of Iran [7, 8] . The α-determinant of HBsAg is a highly conformational, immunodominant antigenic determinant and is common to all HBsAg subtypes. It is located at amino acid positions 124 -147 within the major hydrophilic region (MHR) of HBsAg (see figure 1) .
Several investigators from different parts of the world suggested that mutations within the α-determinant of the S-gene of HBV may change the epitope making it undetectable by routine ELISA methods, hence, these samples are inappropriately being considered as HBsAg negative [9] [10] [11] [12] [13] . In contrast, some researchers failed to report mutations in the αdeterminant of HBsAg in OBI patients [12, [14] [15] [16] . Therefore we decided to carry out additional evaluations of possible mutations in the αdeterminant which, if correlated to the disease, could be a useful tool to identifying the mechanisms of OBI progression. However, other studies have reported all the current HBV genotypes in OBI patients [9, [15] [16] [17] [18] and some investigators suggested that, in OBI, mutations of the S-gene are genotype specific [15] , thus, we also determined the genotype of HBV in the patients that were studied in this report. In addition to these complications, some investigators have indicated that low expression of HBsAg in OBI patients may also render it undetectable by ELISA [12, 19] . One mechanism that may be responsible for low HBsAg expression is co-infection with Hepatitis C (HCV) [19, 20] . Previous studies showed that the HCV core protein can act as a gene-regulatory protein which leads to decreased function of translation machinery of hepatocytes [20] .
In fact, HBsAg can not be expressed in hepatocytes co-infected with both HCV and HBV.
Due to the critical role of HBsAg in detection and clinical diagnosis of HBV infection, this project aimed to investigated the mutations of the Sgene (including the α-determinant), the genotype of HBV and coinfection with HCV in a subset of Iranian OBI patients.
Material and methods:

Subjects
Peripheral blood samples were collected from 3700 volunteer blood donors attending the Rafsanjan Blood Transfusion Services (Kerman, Iran) and placed in 5 ml tubes without anticoagulants. The samples were centrifuged at 370 x g for 4 minutes and the sera collected. All sera were separated within 24 hours of collection. If needed, serum samples were stored at -20ºC for a maximum of 2 months or at -70ºC, where longer storage times were required, for further processing. All of the samples were screened for HBsAg, anti-HBc and HBV-DNA as described previously [5] . In addition, 57 samples were collected from OBI patients Prior to sample collection, all of the participants of this study filled out and signed the informed consent form which was designed based on the aims and objectives of the study.
Sequencing of the S gene
HBV-DNA PCR product was sequenced directly using an automated ABI (Applied Biosystems Incorporation) 0377 sequencer at the sequencing unit of the Cinnagen Company, Iran. HBV reference genome sequences were downloaded from NCBI GenBank.
RNA extraction
0.1ml of blood plasma were added to phenol and vortexed and centrifuged for 5 min at 12000rpm. The upper aqueous phase was transferred to a fresh 1.5ml tube and 0.2ml chloroform was added and mixed vigorously for 15 seconds. The sample was then incubated at room temperature for 5 min, followed by centrifugation at 12000rpm for 15 min at 4°C. The upper aqueous layer (containing RNA) was transferred to a fresh 1.5ml tube and 0.5ml isopropanol was added to the isolated aqueous layer. This mixture was incubated at room temperature for 10 min and the RNA was precipitated by centrifugation at 12,000rpm for 10 min at 4°C. The pellet was washed with 1ml of 75% (v/v) ethanol and centrifuged at 7500rpm for 5 min at 4°C. The resultant pellet was then air-dried for 10-15 min and dissolved in 25-50µl DEPC-treated water (the added volume depended on the size of the pellet) and heated at 60°C for 10 min.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
To make cDNA, a reverse transcription reaction was performed using the 
Genotyping
HBV genotyping was performed as described by Amini et al., 2008 [21] .
The sequences of forward and reverse primers used in this section are shown in table 1.
Results
In the present study we found that all patients were negative for HBsAg, only 352 (9.5%) samples were positive for anti-HBc whereas HBV-DNA was detected in 57 of those 352 samples (16.1% of the HBsAg -/anti-HBc + pool). Therefore, current results indicated that 16.1% of HBsAg -/anti-HBc + samples had detectable HBV-DNA and were regarded as OBI patients. Overall, 1.54% of all donated samples were OBI carriers.
The results of this study demonstrated that there was no mutation in αdeterminant of the S-gene of HBV in occult and acute HBV infected patients but one silent, G369A (Thr123Thr), and a Glycine to Arginine mutation, G553A (Gly185Arg), was observed outside the range of the αdeterminant in both groups as well as a mutation at +580 of HBV S-gene, G580A (Ala194Thr), in acute HBV infected patients (Figure 1 ). We submitted this altered sequence of the S-gene of OBI patients in the NCBI GenBank database (accession number EU346890).
We also found that all of the samples analysed in this study were HCV-RNA negative and genotyping of HBV demonstrated that all patients were infected with the HBV D genotype (Figure 2 ).
Discussion
In OBI, despite undetectable levels of HBsAg, detectable levels of HBV-DNA exist in the peripheral blood of patients [2, 22] . In our previous investigations, we showed a markedly elevated prevalence of OBI in Iranian blood donors compared to some other countries [7, 8] . Our previous results encouraged us to carry out a set of experiments to analyse the possible mechanisms of OBI in Iranian blood donors.
Although, the results of some studies have demonstrated that HCV coinfection may be one of the main reasons for inducing OBI [19, 20] , our results showed that OBI patients were negative for both HCV markers (HCV-Ab -/HCV-RNA -). Therefore, it seems that HCV does not play a prominent role in inducing OBI in our patients. Although, OBI is reported elsewhere in HCV infected patients [23, 24] our previous investigations showed that there was no occurrence of OBI in HCV infected haemodialysis [3] and thalassemic patients [4] . Considering those results it appeared that HCV infection is not prevalent in Iranian OBI patients.
Additionally, Fallahi et al., reported that HCV incidence per 100,000 blood donations was 0.13% in Iran [25] . Suggesting that the incidence of HCV in Iranian blood donors is less than other regional countries [25] .
Therefore, it can be assumed that the low HCV incidence in Iranian blood donors is a significant reason for undetectable HCV in our patients [25] .
Previous studies showed that genotypes of HBV may influence the clinical presentation of hepatitis B [26] . For Instance, Kao et al., 2003, showed that the clinical presentation is different in patients infected with various types of HBV genotypes [27] . In addition, Yuen et al., 2004, showed that C genotype of HBV is associated with hepatocellular carcinoma [28] . Our results showed that all of the patients studied were infected by the D genotype of HBV. In agreement with these results, Katsoulidou et al., 2009 , Van et al., 2008 and Pinarbasi et al., 2009 showed that the D genotype of HBV was present in OBI patients from Greece, the Netherlands and Turkey, respectively [29, 30] . In addition to the D genotype other HBV genotypes, including the C genotype [9, 17, 18] as well as A and G genotypes [15, 18, 31] have been reported in the OBI, thus, it is not possible to conclude that the D genotype is uniquely involved in OBI. Clearly there are other factors to be considered and a more complete study is needed in this field.
Other features of HBV variation that have the potential to induce OBI could include mutations in S-gene that have not been revealed in the current study in this report because any mutations were not seen in the α- [13] . However, the combined data suggests that S-gene mutations are not involved in inducing OBI in our geographical region, hence, it is likely that HBsAg has normal conformational structure and can be detected by standard ELISA protocols being used for blood screening and using more sensitive tests may improve HBsAg detection. Moreover, it would appear that virus related parameters such as mutations in the S-gene or coinfection with HCV do not play prominent role in establishing OBI in our studied patients. Furthermore, we have speculated that possible failures of the immune system to respond during the process of HBV viral clearance could be the main reasons of OBI in our patient population.
Finally, due to the complexity of OBI, different aspects of the disease must be examined. In our future work we will study the expression and polymorphisms within important molecules involved in the immune system of OBI patients. Our preliminary studies suggested that polymorphisms in exon 9 of the vitamin D receptor is associated with OBI [5], suggesting that we focus on genes that regulate immune responses of patients with viral infections. ). The lines below show the nucleotide sequence of the s-gene sequences from patients with occult (labeled 'HBV OBI') and acute (labeled 'HBV acute') hepatitis infections, blank spaces indicate homology with the reference sequence. Both occult and acute infected patients carried mutations G369A (Thr123Thr) and G553A (Gly185Arg). In addition to these mutations, the acute patients also carried G580A (Ala194Thr). The α-determinant region is shown underlined. 
